A curated update with direct links to the evidence
Allergic Bronchopulmonary Aspergillosis (ABPA) and Aspergillus Airway Disease
Several recent papers continue to refine how ABPA is diagnosed and managed, particularly outside classic asthma and cystic fibrosis settings.
A practical treatment overview for ABPA in cystic fibrosis is provided by Thimmesch et al., focusing on steroid strategies and antifungal use
👉 https://pubmed.ncbi.nlm.nih.gov/41537324/
A major narrative review of ABPA and Aspergillus-related airway disease in bronchiectasis reframes ABPA as part of a wider spectrum of Aspergillus-driven lung disease, with implications for earlier recognition
👉 https://pubmed.ncbi.nlm.nih.gov/41522133/
Diagnostic uncertainty remains a major challenge. A comparative study of IgG/IgE ELISA versus serum precipitins highlights strengths and limitations of commonly used tests
👉 https://pubmed.ncbi.nlm.nih.gov/41514182/
Treatment optimisation is addressed in a retrospective cohort study examining glucocorticoid dose, duration, and antifungal combinations in ABPA, showing that regimen choice meaningfully affects outcomes
👉 https://pubmed.ncbi.nlm.nih.gov/41492771/
ABPA is increasingly recognised beyond asthma and cystic fibrosis. A short but influential paper proposes Aspergillus sensitisation and ABPA in COPD as a “treatable trait”
👉 https://pubmed.ncbi.nlm.nih.gov/41520264/
Rare but clinically important overlap is illustrated by a case report describing invasive pulmonary aspergillosis overlapping with ABPA
👉 https://pubmed.ncbi.nlm.nih.gov/41496036/
Chronic Pulmonary Aspergillosis (CPA) and Aspergilloma
A large multicentre cohort study from Brazil provides valuable data on CPA in high tuberculosis-burden settings, documenting delayed diagnosis and significant mortality
👉 https://pubmed.ncbi.nlm.nih.gov/41536616/
Surgical innovation is highlighted in a report describing minimally invasive management of a centrally located pulmonary aspergilloma in an adolescent, showing evolving interventional approaches
👉 https://pubmed.ncbi.nlm.nih.gov/41537646/
CPA caused by non-fumigatus species is increasingly recognised, including a case of Aspergillus candidus infection in a lung cancer patient with heavy smoking history
👉 https://pubmed.ncbi.nlm.nih.gov/41495698/
Invasive Pulmonary Aspergillosis (IPA): Expanding Risk Groups
A comprehensive review describes how IPA is increasingly seen in non-neutropenic patients, challenging traditional risk models
👉 https://pubmed.ncbi.nlm.nih.gov/41515529/
ICU-acquired IPA is examined in a large multicentre cohort stratified by SARS-CoV-2 infection, demonstrating different clinical patterns in COVID-positive and COVID-negative patients
👉 https://pubmed.ncbi.nlm.nih.gov/41526761/
Longitudinal mycological data from ICU patients with influenza- and COVID-associated pulmonary aspergillosis (IAPA and CAPA) show how bronchoalveolar lavage galactomannan kinetics relate to outcome
👉 https://pubmed.ncbi.nlm.nih.gov/41508132/
IPA is not confined to traditional risk groups. A case report documents invasive aspergillosis in a child without identifiable risk factors, reinforcing the need for diagnostic vigilance
👉 https://pubmed.ncbi.nlm.nih.gov/41520716/
Rare manifestations continue to appear, including isolated renal aspergillosis after paediatric stem-cell transplantation
👉 https://pubmed.ncbi.nlm.nih.gov/41508322/
Diagnostics, Resistance, and Drug Safety
Concerns about antifungal resistance are reinforced by a clinical screening study demonstrating azole resistance in Aspergillus isolates
👉 https://pubmed.ncbi.nlm.nih.gov/41528781/
A molecular overview of clinical Aspergillus diversity beyond A. fumigatus highlights implications for pathogenicity and antifungal susceptibility
👉 https://pubmed.ncbi.nlm.nih.gov/41528247/
Drug–drug interactions are explored in depth in a study examining concurrent triazole use with chemotherapy and immunosuppressants in invasive aspergillosis, underlining the importance of monitoring
👉 https://pubmed.ncbi.nlm.nih.gov/41528615/
Unusual but serious adverse effects are illustrated by a case of voriconazole-induced hypoglycaemia in a non-diabetic patient
👉 https://pubmed.ncbi.nlm.nih.gov/41506798/
Cutaneous manifestations as early diagnostic clues are reviewed in a paper on skin signs of invasive fungal disease, including secondary cutaneous aspergillosis
👉 https://pubmed.ncbi.nlm.nih.gov/41505800/
New Therapies and Prevention Strategies
A nationwide French observational study reports real-world outcomes from compassionate use of olorofim in invasive mould infections, including refractory aspergillosis
👉 https://pubmed.ncbi.nlm.nih.gov/41531505/
Economic evidence is emerging alongside clinical data. A cost-utility analysis of preventing invasive aspergillosis in lung transplant recipients supports targeted prophylactic strategies
👉 https://pubmed.ncbi.nlm.nih.gov/41490563/
Fundamental and Translational Aspergillus Research
Several papers advance understanding of Aspergillus fumigatus virulence and regulation, including network-based gene regulation models
👉 https://pubmed.ncbi.nlm.nih.gov/41505094/
A detailed mechanistic study shows how CsdA–LaeB regulatory interactions influence virulence and secondary metabolite production
👉 https://pubmed.ncbi.nlm.nih.gov/41498629/
Vaccine-relevant work explores how cell-wall remodelling alters innate immune recognition in an experimental A. fumigatus strain
👉 https://pubmed.ncbi.nlm.nih.gov/41509434/
Population genomics continues to redefine Aspergillus diversity, including the Aspergillus flavus–oryzae complex, with relevance to both clinical and environmental exposure
👉 https://pubmed.ncbi.nlm.nih.gov/41522572/
One Health and Veterinary Aspergillosis
Aspergillosis remains a One-Health issue, with reports including fungal pericarditis due to Aspergillus fumigatus in dogs
👉 https://pubmed.ncbi.nlm.nih.gov/41521069/
and Aspergillus infections in endangered bird species, highlighting environmental and conservation links
👉 https://pubmed.ncbi.nlm.nih.gov/41497419/
Did this page help you?
Tell us in one minute
